碘西醇 | 81045-33-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 碘西醇
• 中文别名: 碘地醇
• 英文名称: Iodecimol
• 英文别名: 5-[[3-[3,5-bis(1,3-dihydroxypropan-2-ylcarbamoyl)-N-(2-hydroxyethyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2-hydroxyethyl)amino]-1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodobenzene-1,3-dicarboxamide
• CAS: 81045-33-2
• 化学式: C₃₅H₄₄I₆N₆O₁₆
• 分子量: 1566.2
• InChiKey: RHISTIGVAKTTCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  63
• 可旋转键数：
  24
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  359
• 氢给体数：
  14
• 氢受体数：
  16

文献信息

• [EN] AFFINITY-ASSISTED PROTEIN MODIFICATION AND RECYCLING<br/>[FR] MODIFICATION ET RECYCLAGE DE PROTÉINES BASÉS SUR LEUR AFFINITÉ
  申请人：UNIV CALIFORNIA

  公开号：WO2016118770A1

  公开（公告）日：2016-07-28

  The present invention provides methods for preparing a protein conjugate having a defined number of conjugate groups. The method includes: forming a mixture containing a macrocyclic matrix material and a plurality of proteins; eluting the proteins from the macrocyclic matrix material to obtain a first separated protein fraction and a second separated protein fraction, wherein substantially all of the proteins in the first separated protein fraction have the same number of handle moieties; contacting the handle moieties with a conversion reagent under conditions sufficient to convert the handle moieties in the first separated protein fraction to reactive moieties; and contacting the reactive moieties with a conjugation reagent under conditions sufficient to form a plurality of protein conjugates, wherein substantially all of the protein conjugates in the plurality have the same number of conjugate groups. Also disclosed are methods for recovering enzymes and other proteins from mixtures for isolation and/or reuse of the enzymes and proteins.

  本发明提供了制备具有定义数量结合基团的蛋白共轭物的方法。该方法包括：形成含有大环矩阵材料和多种蛋白质的混合物；从大环矩阵材料中洗脱蛋白质，以获得第一分离的蛋白质分数和第二分离的蛋白质分数，其中第一分离的蛋白质分数中几乎所有蛋白质具有相同数量的手柄基团；将手柄基团与转化试剂接触，在足以将第一分离的蛋白质分数中的手柄基团转化为反应性基团的条件下；将反应性基团与结合试剂接触，在足以形成多种蛋白共轭物的条件下，其中多数蛋白共轭物具有相同数量的结合基团。还公开了从混合物中回收酶和其他蛋白质以便分离和/或重复使用酶和蛋白质的方法。
• NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES
  申请人：Rogers Thomas E.

  公开号：US20130066086A1

  公开（公告）日：2013-03-14

  The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.

  本发明提供了膦酸酯共轭物及其制备方法，以便例如改进方法和化合物来修改纳米颗粒的表面，从而增加体内循环时间和靶向传递性能。
• [EN] MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF<br/>[FR] FORMULATIONS DE LIPOSOME DE PROMÉDICAMENT DE MITOMYCINE C ET LEURS UTILISATIONS
  申请人：MALLINCKRODT LLC

  公开号：WO2018089481A1

  公开（公告）日：2018-05-17

  The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.

  本发明提供了用于治疗癌症的MMC前药化合物和脂质体MMC前药及其组合物。该组合物包括含有磷脂酰胆碱脂质、固醇、PEG-脂质和MMC前药的脂质体。本发明还提供了用于治疗癌症的脂质体组合物，包括向需要的患者施用脂质体，其中脂质体包括：磷脂酰胆碱脂质；固醇；PEG-脂质和MMC前药或其药用可接受的盐。
• MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS
  申请人：Mallinckrodt Inc.

  公开号：US20130183236A1

  公开（公告）日：2013-07-18

  The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.

  本发明提供了针对性递送组合物以及使用这些组合物治疗和诊断受试者疾病状态的方法。
• Injectable Radio-Opaque Compositions for Tissue Augmentation
  申请人：Zamparo Enrico

  公开号：US20100284919A1

  公开（公告）日：2010-11-11

  Injectable radio-opaque compositions for tissue augmentation and in particular hard tissue augmentation, and kits and methods of using thereof are described herein. The injectable compositions form porous, biologically degradable, fibrin matrices. The compositions are formed from fibrinogen, thrombin or another agent that causes the fibrinogen to crosslink, and strontium salts. Optionally an iodinated contrast agent is further incorporated in the composition. In certain aspects, the compositions have substantially no exothermicity when forming the matrix and the resulting matrices exhibit mechanical properties typically seen in elastomers. Adequate radio-opacity is achieved through the incorporation of strontium salts in combination or not with iodinated contrast agents.

  本文描述了用于组织增生的可注射放射不透明组合物，特别是用于硬组织增生的组合物，以及使用它们的套件和方法。可注射的组合物形成多孔、生物降解的纤维蛋白基质。这些组合物由纤维蛋白原、凝血酶或其他导致纤维蛋白原交联的药剂，以及锶盐形成。可选择地，在组合物中进一步加入碘造影剂。在某些方面，这些组合物在形成基质时几乎没有放热性，形成的基质具有通常在弹性体中看到的机械性能。通过将锶盐与碘造影剂组合或单独使用，可以实现足够的放射不透明度。